BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 23884781)

  • 21. The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3.
    Li J; Li H; Zhang Z; Wang N; Zhang Y
    Biol Res; 2016 Mar; 49():21. PubMed ID: 27015938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines.
    Dicitore A; Grassi ES; Caraglia M; Borghi MO; Gaudenzi G; Hofland LJ; Persani L; Vitale G
    Endocrine; 2016 Jan; 51(1):101-12. PubMed ID: 25863490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial watch: Immunostimulatory cytokines in cancer therapy.
    Vacchelli E; Aranda F; Obrist F; Eggermont A; Galon J; Cremer I; Zitvogel L; Kroemer G; Galluzzi L
    Oncoimmunology; 2014; 3():e29030. PubMed ID: 25083328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukins as markers of inflammation in malignant and benign thyroid disease.
    Provatopoulou X; Georgiadou D; Sergentanis TN; Kalogera E; Spyridakis J; Gounaris A; Zografos GN
    Inflamm Res; 2014 Aug; 63(8):667-74. PubMed ID: 24794392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma.
    Vitale G; Tagliaferri P; Caraglia M; Rampone E; Ciccarelli A; Bianco AR; Abbruzzese A; Lupoli G
    J Clin Endocrinol Metab; 2000 Mar; 85(3):983-8. PubMed ID: 10720027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
    Díez JJ; Iglesias P
    J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
    Faggiano A; Modica R; Severino R; Camera L; Fonti R; Del Prete M; Chiofalo MG; Aria M; Ferolla P; Vitale G; Pezzullo L; Colao A
    Endocrine; 2018 Oct; 62(1):46-56. PubMed ID: 29572709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of a Novel Second-Generation Somatostatin-Dopamine Chimera (TBR-065) in Human Medullary Thyroid Cancer: A Preclinical Study.
    Dicitore A; Cantone MC; Gaudenzi G; Saronni D; Carra S; Borghi MO; Albertelli M; Ferone D; Hofland LJ; Persani L; Vitale G
    Neuroendocrinology; 2021; 111(10):937-950. PubMed ID: 33075795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
    Zatelli MC; Piccin D; Tagliati F; Bottoni A; Luchin A; Vignali C; Margutti A; Bondanelli M; Pansini GC; Pelizzo MR; Culler MD; Degli Uberti EC
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2218-24. PubMed ID: 16569735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
    Vitale G; Lupoli G; Guarrasi R; Colao A; Dicitore A; Gaudenzi G; Misso G; Castellano M; Addeo R; Facchini G; Del Prete S; Caraglia M
    J Clin Endocrinol Metab; 2013 Oct; 98(10):E1567-74. PubMed ID: 23884781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medullary thyroid carcinoma and hormones.
    Cohen R; Quidville V; Bihan H
    Ann Med Interne (Paris); 2003 Mar; 154(2):109-16. PubMed ID: 12746649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on medullary thyroid cancer.
    Hu MI; Ying AK; Jimenez C
    Endocrinol Metab Clin North Am; 2014 Jun; 43(2):423-42. PubMed ID: 24891170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT.
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):13-5. PubMed ID: 27168107
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.